KR940018372A - 피페라진 유도체 - Google Patents
피페라진 유도체 Download PDFInfo
- Publication number
- KR940018372A KR940018372A KR1019940001512A KR19940001512A KR940018372A KR 940018372 A KR940018372 A KR 940018372A KR 1019940001512 A KR1019940001512 A KR 1019940001512A KR 19940001512 A KR19940001512 A KR 19940001512A KR 940018372 A KR940018372 A KR 940018372A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- chr
- physiologically acceptable
- general formula
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 208000007536 Thrombosis Diseases 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- -1 imidazolylmethyl Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 2
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims 2
- 125000006301 indolyl methyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- XBGVMSACSDXRHA-UHFFFAOYSA-N 3-[[3-[[2-(4-carbamimidoylpiperazin-1-yl)acetyl]amino]benzoyl]amino]propanoic acid Chemical compound C1CN(C(=N)N)CCN1CC(=O)NC1=CC=CC(C(=O)NCCC(O)=O)=C1 XBGVMSACSDXRHA-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
하기 일반식(Ⅰ)의 신규 피레라진 유도체는 피브리노겐 수용체에의 피브리노겐의 결합을 억제하며 혈전증, 중풍, 심근경색, 염증, 죽상동맥경화증 및 종양의 치료에 사용될 수 있다:
Y-(CmH2m-CHR1)n-CO-(NH-CHR2-CO)r-Z (Ⅰ)
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 하기 일반식(Ⅰ)의 화합물 및 그의 염:Y-(CmH2m-CHR1)n-CO-(NH-CHR2-CO)r-Z (Ⅰ)상기식에서, Y는또는이고, Z는이거나 또는 Y가인 경우,이고, R1, R2및 R3은 각각 -CtH2t-R9, 벤질, 하이드록시벤질, 이미다졸릴메틸 또는 인돌릴메틸이고, R3는 H 또는 H1N-C(=NH)-이고, R4및 R6은 각각(H,H) 또는 =0 이고, R5는 H, H2N-C(=NH)-또는 H2N-C(=NH)-NH이고, R8은 OH, OA 또는 NHOH이고, R9는 H, OH, NH2, SH, SA, COOH, CONH2또는 NH-C(=NH)-NH2이고, A는 각 경우에 탄소원자수 1 내지 4의 알킬이고, m 및 t는 각각 0, 1, 2, 3 또는 4이고, n 및 r은 각각 0 또는 1이고, p는 0, 1 또는 2이고, 피페라진 고리는 1내지 4의 그룹 A로 치환될 수 있다.
- 3-(3-(4-아미디노피페라진-1-일아세트아미도)벤즈아미도)프로피온산.
- a)일반식(Ⅰ)의 화합물을 가용매분해제 또는 가수소분해제로 처리하여 그의 작용성 유도체중의 하나로 부터 유리시키거나 또는 b)하기 일반식(Ⅱ)의 가복실산 또는 그의 반응성 유도체중의 하나를 하기 일반식(Ⅲ)이 아미노 화합물과 반응시키거나, (c)R3또는 R5가 H2N-C(=NH)-인 일반식(Ⅰ)의 화합물을 제조하기 위하여, 라디칼 R3또는 R5대신에 CN그룹을 포함함을 제외하곤 일반식(Ⅰ)을 갖는 니트릴에 암모니아를 첨가하고, 및/또는 경우에 따라, 일반식(Ⅰ)의 카복실산(R8-OH)을 대응 에스테르(I, R8=OA)로 전환시키거나 또는 대응 하이드록삼산(I, R8=NHOH)로 전환시키고/시키거나, H원자를 아미딘-형성제로 처리하여 아미디노 그룹으로 대체하거나, 또는 일반식(Ⅰ)(R8=OA)에 에스테르를 비누화하고/하거나, 일반식(Ⅰ)의 화합물을 산 또는 염기로 처리하여 그의 염중의 하나로 전환시킴을 특징으로 하는, 일반식(Ⅰ)의 화합물 및 그의 염을 제조하는 방법.Y-(CmH2m-CHR1)n-CO-(NH-CHR2-CO)r-Z (Ⅰ)Y-(CmH2m-CHR1)n-CO-G1-OH(Ⅱ)H-G2(Ⅲ)[상기식에서, G1은 1)존재하지 않거나, 2)-NH-CHR2-CO- 또는 3)이고, G2는 1)-(NH-CHR2-CO)r-Z, 2)Z 또는 3)-NH-CpH2p-CHR7-CO-R8이고, Y는또는이고, Z는이거나 또는 Y가인 경우,이고, R1, R2및 R3은 각각 -CtH2t-R9, 벤질, 하이드록시벤질, 이미다졸릴메틸 또는 인돌릴메틸이고, R3는 H 또는 H2N-C(=NH)-이고, R4및 R6은 각각(H,H) 또는 =0 이고, R5는 H, H2N-C(=NH)-또는 H2N-C(=NH)-NH이고, R8은 OH, OA 또는 NHOH이고, R9는 H, OH, NH2, SH, SA, COOH, CONH2또는 NH-C(=NH)-NH2이고, A는 각 경우에 탄소원자수 1 내지 4의 알킬이고, m 및 t는 각각 0, 1, 2, 3 또는 4이고, n 및 r은 각각 0 또는 1이고, p는 0, 1 또는 2이고, 피페라진 고리는 1내지 4의 그룹 A로 치환될 수 있다.
- 제 1 항에 따른 일반식(Ⅰ)의 화합물 및/또는 그의 생리학적으로 허용가능한 염을 적어도 하나의 고체, 액체 또는 반고체의 부형제 또는 보조제와 함께 적합한 투여형으로 전환시킴을 특징으로 하는 약학적 제제의 제조방법.
- 적어도 하나의 제 1 항에 따른 일반식(Ⅰ)의 화합물 및/또는 그의 생리학적으로 허용가능한 염을 포함함을 특징으로 하는 약학적 제제.
- 약제를 제조하기 위한 제 1 항에 따른 일반식(Ⅰ)의 화합물 또는 그의 생리학적으로 허용가능한 염의 용도.
- 혈전증, 심근경색증, 중풍, 골다공증, 죽상동맥경화증, 염증 및/또는 종양의 치료하기 위한 제 1 항에 따른 일반식(Ⅰ)의 화합물 또는 그의 생리학적으로 허용가능한 염의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4302485A DE4302485A1 (de) | 1993-01-29 | 1993-01-29 | Piperazinderivate |
| DEP4302485.8 | 1993-01-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR940018372A true KR940018372A (ko) | 1994-08-16 |
| KR100312539B1 KR100312539B1 (ko) | 2002-02-19 |
Family
ID=6479203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940001512A KR100312539B1 (ko) | 1993-01-29 | 1994-01-28 | 피페라진유도체 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5908843A (ko) |
| EP (1) | EP0608759B1 (ko) |
| JP (1) | JPH06271549A (ko) |
| KR (1) | KR100312539B1 (ko) |
| CN (1) | CN1056141C (ko) |
| AT (1) | ATE204570T1 (ko) |
| AU (1) | AU670649B2 (ko) |
| CA (1) | CA2114361A1 (ko) |
| CZ (1) | CZ288122B6 (ko) |
| DE (2) | DE4302485A1 (ko) |
| DK (1) | DK0608759T3 (ko) |
| ES (1) | ES2162825T3 (ko) |
| GR (1) | GR3036838T3 (ko) |
| HU (1) | HU222013B1 (ko) |
| NO (1) | NO312550B1 (ko) |
| PL (1) | PL172716B1 (ko) |
| PT (1) | PT608759E (ko) |
| RU (1) | RU2154639C2 (ko) |
| SK (1) | SK281842B6 (ko) |
| UA (1) | UA34429C2 (ko) |
| ZA (1) | ZA94615B (ko) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| JP2000504336A (ja) | 1996-02-02 | 2000-04-11 | ゼネカ・リミテッド | 薬学製剤として有用なヘテロ環式化合物 |
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| GB9602294D0 (en) * | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
| DE69736669T2 (de) * | 1996-07-25 | 2007-09-13 | Biogen Idec Ma Inc., Cambridge | Zelladhäsionsinhibitoren |
| BR9711135A (pt) * | 1996-08-14 | 1999-08-17 | Zeneca Ltd | Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento |
| UA56197C2 (uk) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
| EP0966462B1 (en) | 1997-02-13 | 2003-06-11 | AstraZeneca AB | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
| AU5999698A (en) | 1997-02-13 | 1998-09-08 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
| GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| DE19743435A1 (de) * | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| FR2781221B1 (fr) * | 1998-07-17 | 2000-10-13 | Lafon Labor | Piperazinones substituees en alpha |
| FR2781220B1 (fr) * | 1998-07-17 | 2000-10-13 | Lafon Labor | Piperazinones substituees en beta |
| DE19835950A1 (de) * | 1998-08-08 | 2000-02-10 | Merck Patent Gmbh | Piperazinonderivate |
| GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
| US6713472B1 (en) | 1999-07-26 | 2004-03-30 | Santen Pharmaceutical Co., Ltd. | Thiazine or pyrazine derivatives |
| PL374971A1 (en) * | 2002-08-09 | 2005-11-14 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| JP2006526633A (ja) * | 2003-06-02 | 2006-11-24 | サマリタン，ファーマスーティカルス，インク． | 抗ｈｉｖ性ベンズアミド化合物 |
| US20060194814A1 (en) * | 2003-06-02 | 2006-08-31 | Vassilios Papadopoulos | Benzamide compounds |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) * | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| TW200738701A (en) * | 2005-07-26 | 2007-10-16 | Du Pont | Fungicidal carboxamides |
| EP1909797A4 (en) * | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
| EP3897635A4 (en) | 2018-12-19 | 2022-08-31 | Celgene Corporation | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF |
| TWI820276B (zh) | 2018-12-19 | 2023-11-01 | 美商西建公司 | 經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3711335A1 (de) * | 1987-04-03 | 1988-10-20 | Merck Patent Gmbh | Aminosaeurederivate |
| US5053393A (en) * | 1988-07-20 | 1991-10-01 | Monsanto Company | Novel platelet-aggregation inhibitor |
| US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
| DE4007869A1 (de) * | 1990-03-13 | 1991-09-19 | Merck Patent Gmbh | Aminosaeurederivate |
| IL99537A (en) * | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
| AU646966B2 (en) * | 1991-08-23 | 1994-03-10 | Takeda Chemical Industries Ltd. | 2-piperazinone compounds, their production and use |
| JP3719612B2 (ja) * | 1993-06-14 | 2005-11-24 | 塩野義製薬株式会社 | ヘテロ環を含有する尿素誘導体 |
-
1993
- 1993-01-29 DE DE4302485A patent/DE4302485A1/de not_active Withdrawn
- 1993-11-30 UA UA93003858A patent/UA34429C2/uk unknown
-
1994
- 1994-01-18 JP JP6003451A patent/JPH06271549A/ja active Pending
- 1994-01-19 DK DK94100709T patent/DK0608759T3/da active
- 1994-01-19 EP EP94100709A patent/EP0608759B1/de not_active Expired - Lifetime
- 1994-01-19 PT PT94100709T patent/PT608759E/pt unknown
- 1994-01-19 AT AT94100709T patent/ATE204570T1/de not_active IP Right Cessation
- 1994-01-19 DE DE59409833T patent/DE59409833D1/de not_active Expired - Fee Related
- 1994-01-19 ES ES94100709T patent/ES2162825T3/es not_active Expired - Lifetime
- 1994-01-20 SK SK68-94A patent/SK281842B6/sk unknown
- 1994-01-25 AU AU54702/94A patent/AU670649B2/en not_active Ceased
- 1994-01-25 CZ CZ1994163A patent/CZ288122B6/cs unknown
- 1994-01-25 CN CN94101127A patent/CN1056141C/zh not_active Expired - Fee Related
- 1994-01-27 CA CA002114361A patent/CA2114361A1/en not_active Abandoned
- 1994-01-28 NO NO19940308A patent/NO312550B1/no not_active IP Right Cessation
- 1994-01-28 HU HU9400249A patent/HU222013B1/hu not_active IP Right Cessation
- 1994-01-28 KR KR1019940001512A patent/KR100312539B1/ko not_active IP Right Cessation
- 1994-01-28 RU RU94002323/04A patent/RU2154639C2/ru not_active IP Right Cessation
- 1994-01-28 PL PL94302069A patent/PL172716B1/pl unknown
- 1994-01-28 ZA ZA94615A patent/ZA94615B/xx unknown
- 1994-01-31 US US08/189,385 patent/US5908843A/en not_active Expired - Fee Related
-
2001
- 2001-10-09 GR GR20010401700T patent/GR3036838T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE204570T1 (de) | 2001-09-15 |
| CN1056141C (zh) | 2000-09-06 |
| DE59409833D1 (de) | 2001-09-27 |
| CZ16394A3 (en) | 1994-08-17 |
| GR3036838T3 (en) | 2002-01-31 |
| PT608759E (pt) | 2002-02-28 |
| NO312550B1 (no) | 2002-05-27 |
| EP0608759B1 (de) | 2001-08-22 |
| UA34429C2 (uk) | 2001-03-15 |
| CN1099759A (zh) | 1995-03-08 |
| SK281842B6 (sk) | 2001-08-06 |
| AU670649B2 (en) | 1996-07-25 |
| SK6894A3 (en) | 1994-08-10 |
| HUT70042A (en) | 1995-09-28 |
| NO940308D0 (no) | 1994-01-28 |
| ZA94615B (en) | 1994-09-13 |
| DE4302485A1 (de) | 1994-08-04 |
| JPH06271549A (ja) | 1994-09-27 |
| US5908843A (en) | 1999-06-01 |
| NO940308L (no) | 1994-08-01 |
| KR100312539B1 (ko) | 2002-02-19 |
| DK0608759T3 (da) | 2001-12-03 |
| EP0608759A3 (de) | 1994-10-05 |
| CA2114361A1 (en) | 1994-07-30 |
| PL302069A1 (en) | 1994-08-08 |
| RU2154639C2 (ru) | 2000-08-20 |
| HU222013B1 (hu) | 2003-03-28 |
| PL172716B1 (pl) | 1997-11-28 |
| EP0608759A2 (de) | 1994-08-03 |
| ES2162825T3 (es) | 2002-01-16 |
| AU5470294A (en) | 1994-08-04 |
| HU9400249D0 (en) | 1994-05-30 |
| CZ288122B6 (cs) | 2001-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940018372A (ko) | 피페라진 유도체 | |
| SE8302130D0 (sv) | Farmakologiskt aktiva bifosfonater, forfarande for deras framstellning och farmaceutiska kompositioner innehallande desamma | |
| SE7900987L (sv) | Alkylendiamin-derivat | |
| KR890005035A (ko) | 벤조일아미노페녹시부탄산 유도체와 그의 제조방법 및 이를 포함하는 제약조성물 | |
| SE8702330L (sv) | Foreningar avsedda att anvendas som mellanprodukt for framstellning av 3-amino-2-oxo-azetidin-1-sulfonsyror | |
| IL99213A0 (en) | Codeine salt of a substituted carboxylic acid,processes for the preparation thereof,its use and pharmaceutical compositions | |
| PT97395A (pt) | Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem | |
| SE8204640D0 (sv) | Aminosyraderivat | |
| IL113011A (en) | R-mandelic acid salt of (2s,3s)-3- (2-methoxybenzylamino)-2- phenylpiperidine | |
| RU98103388A (ru) | (r)-5-бром-n-(1-этил-4-метилгексагидро-1н-1,4-диазепин-6-ил)-2-метокси-6-м етиламино-3-пиридинкарбоксамид, способ его получения и фармацевтическая композиция, содержащая указанное соединение | |
| SE8406554D0 (sv) | New gonadoliberin derivatives and process for the preparation thereof | |
| ES2038596T3 (es) | Un procedimiento para la preparacion de nuevos compuestos heterociclicos. | |
| RU94031479A (ru) | Новое применение производных аминокислот, способ лечения, фармацевтическая композиция | |
| HK1000284A1 (en) | N-(5,6,7,8-tetrahydropyrido(2,3D)pyrimidin-6-Yl-alkanoyl)-glutamic acid derivatives | |
| KR960029319A (ko) | 4-아미노벤조일구아니딘 유도체 | |
| IL71068A (en) | N-(3-trifluoromethylphenyl)-n'-propargyl-piperazine,its preparation and pharmaceutical compositions containing it | |
| DE69405999T2 (de) | Pharmazeutisch wirksame enantiomere | |
| KR950702557A (ko) | 신규의 진통제 및 누트로픽 약물 | |
| KR880013891A (ko) | 모노아민 옥시다아제 억제용 전구체로서의 β-(플루오로메틸렌)-5-하이드록시트립토판 및 유도체 | |
| CH613933A5 (en) | Process for the preparation of [1-oxo-2-aryl- or -thienyl-2-subst.-5-indanyloxy- (or -thio)]alkanecarboxylic acids or their alkyl esters | |
| KR960029321A (ko) | 4-메르캅토벤조일구아니딘 유도체 | |
| MX174421B (es) | Procedimiento para la preparacion de 4-arilcarbonil-1-[(4-morfolinil)-alquilo-inferior]-1h-indoles y producto obtenido | |
| AU7384381A (en) | Substituted oxadiazoles | |
| KR950032151A (ko) | 점착성 수용체 길항제 | |
| IES950207A2 (en) | Process for the resolution of racemic 3-(2-pyridyl)-3-phenyl-N,N-dimethylpropylamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |